419 related articles for article (PubMed ID: 32963090)
1. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.
Azam TU; Shadid HR; Blakely P; O'Hayer P; Berlin H; Pan M; Zhao P; Zhao L; Pennathur S; Pop-Busui R; Altintas I; Tingleff J; Stauning MA; Andersen O; Adami ME; Solomonidi N; Tsilika M; Tober-Lau P; Arnaoutoglou E; Keitel V; Tacke F; Chalkias A; Loosen SH; Giamarellos-Bourboulis EJ; Eugen-Olsen J; Reiser J; Hayek SS;
J Am Soc Nephrol; 2020 Nov; 31(11):2725-2735. PubMed ID: 32963090
[TBL] [Abstract][Full Text] [Related]
2. Acute kidney injury associated with COVID-19: A retrospective cohort study.
Kolhe NV; Fluck RJ; Selby NM; Taal MW
PLoS Med; 2020 Oct; 17(10):e1003406. PubMed ID: 33125416
[TBL] [Abstract][Full Text] [Related]
3. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study.
Fisher M; Neugarten J; Bellin E; Yunes M; Stahl L; Johns TS; Abramowitz MK; Levy R; Kumar N; Mokrzycki MH; Coco M; Dominguez M; Prudhvi K; Golestaneh L
J Am Soc Nephrol; 2020 Sep; 31(9):2145-2157. PubMed ID: 32669322
[TBL] [Abstract][Full Text] [Related]
4. suPAR as a marker of infection in acute kidney injury - a prospective observational study.
Hall A; Crichton S; Varrier M; Bear DE; Ostermann M
BMC Nephrol; 2018 Aug; 19(1):191. PubMed ID: 30071826
[TBL] [Abstract][Full Text] [Related]
5. Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications.
Zahid U; Ramachandran P; Spitalewitz S; Alasadi L; Chakraborti A; Azhar M; Mikhalina G; Sherazi A; Narh JT; Khattar P; Bedi P
Am J Nephrol; 2020; 51(10):786-796. PubMed ID: 33011717
[TBL] [Abstract][Full Text] [Related]
6. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
[TBL] [Abstract][Full Text] [Related]
7. Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
Mossanen JC; Pracht J; Jansen TU; Buendgens L; Stoppe C; Goetzenich A; Struck J; Autschbach R; Marx G; Tacke F
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758975
[TBL] [Abstract][Full Text] [Related]
8. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
Oulhaj A; Alsuwaidi AR; Suliman A; Gasmelseed H; Khan S; Alawi S; Hukan Y; George J; Alshamsi F; Sheikh F; Babiker ZOE; Prattes J; Sourij H
Int J Infect Dis; 2021 Jun; 107():188-194. PubMed ID: 33862208
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
Rovina N; Akinosoglou K; Eugen-Olsen J; Hayek S; Reiser J; Giamarellos-Bourboulis EJ
Crit Care; 2020 Apr; 24(1):187. PubMed ID: 32354367
[No Abstract] [Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients.
Padelli M; Gueye P; Guilloux D; Banydeen R; Campana V; Cabie A; Neviere R
Biomark Med; 2022 Feb; 16(3):169-177. PubMed ID: 35081737
[TBL] [Abstract][Full Text] [Related]
11. The incidence, risk factors and prognosis of acute kidney injury in severe and critically ill patients with COVID-19 in mainland China: a retrospective study.
Sang L; Chen S; Zheng X; Guan W; Zhang Z; Liang W; Zhong M; Jiang L; Pan C; Zhang W; Xia J; Chen N; Wu W; Wu H; Xu Y; Liu X; Liu X; He J; Li S; Zhang D; Zhong N; Li Y
BMC Pulm Med; 2020 Nov; 20(1):290. PubMed ID: 33167955
[TBL] [Abstract][Full Text] [Related]
12. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
Luo S; Vasbinder A; Du-Fay-de-Lavallaz JM; Gomez JMD; Suboc T; Anderson E; Tekumulla A; Shadid H; Berlin H; Pan M; Azam TU; Khaleel I; Padalia K; Meloche C; O'Hayer P; Catalan T; Blakely P; Launius C; Amadi KM; Pop-Busui R; Loosen SH; Chalkias A; Tacke F; Giamarellos-Bourboulis EJ; Altintas I; Eugen-Olsen J; Williams KA; Volgman AS; Reiser J; Hayek SS;
J Am Heart Assoc; 2022 Sep; 11(18):e025198. PubMed ID: 35924778
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury.
Zhang W; Gu Y; Zhou J; Wang J; Zhao X; Deng X; Li H; Yan L; Jiao X; Shao F
Ren Fail; 2024 Dec; 46(1):2307959. PubMed ID: 38289005
[TBL] [Abstract][Full Text] [Related]
14. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.
Liao TH; Wu HC; Liao MT; Hu WC; Tsai KW; Lin CC; Lu KC
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142634
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Reisinger AC; Niedrist T; Posch F; Hatzl S; Hackl G; Prattes J; Schilcher G; Meißl AM; Raggam RB; Herrmann M; Eller P
Sci Rep; 2021 Sep; 11(1):17476. PubMed ID: 34471146
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of suPAR and hsCRP on acute kidney injury after cardiac surgery.
Rasmussen SR; Nielsen RV; Møgelvang R; Ostrowski SR; Ravn HB
BMC Nephrol; 2021 Apr; 22(1):120. PubMed ID: 33827466
[TBL] [Abstract][Full Text] [Related]
17. Soluble Urokinase Receptor and Acute Kidney Injury.
Hayek SS; Leaf DE; Samman Tahhan A; Raad M; Sharma S; Waikar SS; Sever S; Camacho A; Wang X; Dande RR; Ibrahim NE; Baron RM; Altintas MM; Wei C; Sheikh-Hamad D; Pan JS; Holliday MW; Januzzi JL; Weisbord SD; Quyyumi AA; Reiser J
N Engl J Med; 2020 Jan; 382(5):416-426. PubMed ID: 31995687
[TBL] [Abstract][Full Text] [Related]
18. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia.
Pei G; Zhang Z; Peng J; Liu L; Zhang C; Yu C; Ma Z; Huang Y; Liu W; Yao Y; Zeng R; Xu G
J Am Soc Nephrol; 2020 Jun; 31(6):1157-1165. PubMed ID: 32345702
[TBL] [Abstract][Full Text] [Related]
19. Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients.
Lippi G; Henry BM; Favaloro EJ
Clin Chem Lab Med; 2021 Oct; 59(11):e413-e415. PubMed ID: 34116589
[No Abstract] [Full Text] [Related]
20. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.
Sarif J; Raychaudhuri D; D'Rozario R; Bandopadhyay P; Singh P; Mehta P; Hoque MA; Sinha BP; Kushwaha M; Sahni S; Devi P; Chattopadhyay P; Paul SR; Ray Y; Chaudhuri K; Banerjee S; Majumdar D; Saha B; Sarkar BS; Bhattacharya P; Chatterjee S; Paul S; Ghosh P; Pandey R; Sengupta S; Ganguly D
Front Immunol; 2021; 12():738093. PubMed ID: 34777349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
